Latest Zidovudine Stories

WASHINGTON, Aug. 24, 2011 /PRNewswire-USNewswire/ -- To stem the estimated 2.6 million new HIV infections that occur worldwide each year, more than 200 representatives from the scientific and HIV/AIDS communities took an important step in assessing the safety and public health implications of providing antiretroviral drugs to uninfected men and women exposed to HIV through sexual contact - a strategy called pre-exposure prophylaxis, or PrEP. Assembling August 19 at an open public meeting...

Another large national organization, The FAIR Foundation, and its 27 member Board of Directors of surgeons, medical directors, dentists and patient advocates, applauds the recent call to Congress by the Traditional Values Coalition (TVC) urging Congress to freeze National Institutes of Health (NIH) funding for six months while investigating the NIH's research practices that are "striking working families across America as wasteful, illicit, and in many cases outright...

(Ivanhoe Newswire) -- A new study suggests that starting antiretroviral therapy earlier leads to better health outcomes and a lower risk of transmitting HIV.According to the World Health Organization, about 33.3 million people were living with HIV in 2009. Antiretroviral therapy has led to huge reductions in death rates and health problems among those who are infected with the virus.Researchers studied 1,763 couples in nine different countries. In each couple, one partner was HIV-1-positive,...

Researchers presenting late breaking research on the final day of the 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011) have today focussed on new studies in the field of circumcision, pre-exposure prophylaxis (PrEP) and antiretroviral treatment. The IAS 2011 conference has been attended by over 5000 researchers, clinicians and community leaders since Sunday in Rome.    * The roll-out of male circumcision in the South African township of Orange Farm (ANRS...

Researchers speaking on the final day of the 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011) have focused on the growing interest in the scientific path to an HIV Cure. Discussions around an HIV cure have been growing over the past 12 months and are now gaining momentum with the establishment of an International AIDS Society (IAS) convened working group concentrating its initial efforts on establishing a global scientific strategy. A number of abstracts have...

In sub-Saharan Africa, only about one third of patients who test positive for HIV but are not yet eligible for antiretroviral treatment remain in care until they become eligible and start treatment. Some patients never return for the results of their initial CD4 count (a prognostic and treatment eligibility biomarker); some disappear between having their initial CD4 count taken and becoming eligible for HIV treatment; and others with CD4 counts that indicate that they are eligible for...

A special press conference at the 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011) will today feature a panel consisting of researchers from the CDC TDF2 study, the Partners PrEP Study and the HPTN 052 study. They will be joined by Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases (NIAID), Gottfried Hirnschall, Director of the HIV Department of the World Health Organization (WHO) and Elly Katabira, IAS 2011 International Chair and...

(Ivanhoe Newswire) "“ Recent successes in HIV prevention emphasize the need for combined approaches for epidemic control. Some of the recent developments to transform the HIV prevention landscape include the success of antiretroviral-based HIV prevention, including topical and oral pre-exposure prophylaxis and treatment for prevention, along with the modest success of a HIV vaccine.Authors of the HIV Special Issue of The Lancet say these and other developments, along with a difficult...

A press release from PLoS ONEA new study by investigators from the University of North Carolina at Chapel Hill School of Medicine has confirmed the existence of a "trial effect" in clinical trials for treatment of HIV.Trial effect is an umbrella term for the benefit experienced by study participants simply by virtue of their participating in the trial. It includes the benefit of newer and more effective treatments, the way those treatments are delivered, increased care and...

In a result that will fundamentally change approaches to HIV prevention in Africa, an international study has demonstrated that individuals at high risk for HIV infection who took a daily tablet containing an HIV medication "“ either the antiretroviral medication tenofovir or tenofovir in combination with emtricitabine "“ experienced significantly fewer HIV infections than those who received a placebo pill. These findings are clear evidence that this new HIV prevention strategy, called...